I will speak a little about regional trade agreements and other free trade agreements between rich countries and developing ones. Outside the World Trade Organisation, which provides the multilateral framework for trade rules and the international trading system, there has been a proliferation of other trading agreements — free trade and regional trade agreements — between rich countries in the north and southern ones. We have some major concerns about some of these agreements.
There are approximately 250 regional and bilateral trade agreements which now cover approximately 30% of international trade, so a very significant amount of international commerce is governed by these non-WTO agreements. By their very nature, they go above and beyond the WTO trade rules which, essentially, lay the basic framework for international trade. In the proper circumstances, some of these trade agreements can be beneficial. The European Union has one such trading arrangement which has gone much further than WTO negotiations.
However, our main concern is around these agreements between northern rich countries, such as the United States and those in Europe, and southern developing countries. At the WTO, there are multilateral negotiations where groups of developing countries can come together, fight their corner and, more successfully as we have seen in this round of negotiations, fight off the demands of rich countries, although there is still a huge imbalance. In bilateral trading agreements between rich countries and developing ones, essentially poor countries are left on their own to face the economic might of the United States or Europe. Their negotiating weight in these relationships is much less than it is, or could be, at the World Trade Organisation.
I will give one simple example of where we have concerns. If one looks at the trading arrangements of the United States in the series of bilateral trade agreements which it has made, or is in the process of making, with a number of developing countries, such as Thailand, Jordan, Bolivia, Colombia and Peru, we have very serious concerns about the impact that will have on access to medicines. The access to medicines issue comes under the rubric of intellectual property. The United States has gone beyond WTO rules where there are certain flexibilities to protect access to medicines and the public's access to medicines as carve outs from intellectual property rules. In the bilateral agreements, however, the United States has systematically attempted to further intellectual property rules and provide greater protection for pharmaceutical companies and longer monopolies on their patents for pharmaceutical products. The results have serious consequences for the possibility of poor people accessing medicines.
I will provide a couple of examples of studies where we might see an impact. I refer to the United States-Colombia free trade agreement. The Pan-American Health Organisation has done a study on what impact it will have if this agreement is ratified and comes into effect. Its study confirms that by 2020, the Colombian health system will pay an additional €940 million per annum to cover the cost of medicines and around 6 million users will have no access to medicines through the public health system. That is a very profound impact for a very basic good. After all in the developing world, poor people generally pay health care costs out of pocket and medicines are a significant element of health care costs.
In Peru, prices for medicines would rise 9.6% on average in the first year, 100% in ten years and 162% in 18 years. In ten years, Peru would incur additional medicine expenses of €199 million, of which €110 million would have to be met by Peruvian households. Again, there would be considerable extra costs on poor countries as a result of these bilateral trade deals. This also contradicts the spirit of the Doha Declaration on access to medicines concluded by nations in 2001 which was supposed to solve some of the problems which arose from the TRIPS agreement.
In Europe, we have a number of existing bilateral trade deals with South Africa, Chile, Mexico and various Mediterranean countries. As David O'Sullivan pointed out before Christmas, we are in the process of beginning negotiations with a series of other countries, such as India which provides the bulk of generic medicines for developing countries — that is, cheap medicines — which would be affected by any such strict intellectual property rules.
We have new agreements with ASEAN, the Association of South East Asian Nations, as well as Central America, the Andean countries and the economic partnership agreements with ACP countries. We are very much in the process of concluding deals. If the European Union goes down the route — it is by no means certain it will — of the United States, then we could see even further impacts for poor people in terms of their access to medicines.
There are other issues in bilateral agreements, such as the right to regulate and the possibility of accessing services which can be affected by bilateral trade agreements. However, I will not go into them unless members have further questions. Mr. Joyce will speak about one of these agreements — economic partnership agreements — which affect African, Caribbean and Pacific countries and some of our priority eight partners, in particular.